TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: DBS Under General Anesthesia: Comparison To The Standard Technique

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient's who have undergone DBS surgery under general anesthesia without electrophysiology, utilizing a portable head CT scanner to verify accuracy intra-operatively.~Exclusion Criteria:~* Patient's who have undergone DBS surgery awake, without general anesthesia and with electrophysiology.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Obtained written informed consent~2. Patients must have histologically confirmed peripheral T-cell lymphoma according to the 2016 revision of the World Health Organization classiﬁcation of lymphoid neoplasms. Tumor samples are required for central pathology review to confirm the diagnosis.~3. Patients must have measurable disease according to the Lugano criteria.~4. Patients should be transplant-ineligible upon their entry into this study, and must have relapsed after or been refractory/intolerant to ≥ 1 (but not \> 3) prior systemic therapy(ies) for PTCL.~5. Adequate bone marrow reserve and organ system functions.~Exclusion Criteria:~1. Any unsolved toxicity \> Common Terminology Criteria for Adverse Events (CTCAE) grade 1 from previous anti-cancer therapy (except alopecia).~2. Active infections, active or latent tuberculosis.~3. Patients with severely decreased lung function.~4. History of heart failure or QT interval prolongation.~5. Central nervous system (CNS) or leptomeningeal lymphoma.~6. History of treatment with Janus kinase (JAK) or signal transducer and activator of transcription 3 (STAT3) inhibitor.~7. Patient has undergone an allogeneic stem cell transplant. Patient had autologous stem cell transplant within 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZD4205 Group A (Type: EXPERIMENTAL): Group A: Open label AZD4205 at dose A, once daily (Phase 1)
- AZD4205 Group B (Type: EXPERIMENTAL): Group B: Open label AZD4205 at dose B, once daily (Phase 1)
- AZD4205 Group C (Type: EXPERIMENTAL): Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)
- AZD4205 Group D (Type: EXPERIMENTAL): Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, at least 18 years of age at time of Screening.~2. Screening laboratory result indicating Hepatitis C virus (HCV) genotype (GT)1-, 2-, 3-, 4-, 5-, or 6-infection.~3. Subject has positive anti-HCV antibody (Ab) and plasma HCV ribonucleic acid (RNA) viral load greater than or equal to 1000 IU/mL at Screening visit.~4. Subjects must be HCV treatment-naïve (i.e., subject has never received a single dose of any approved or investigational anti-HCV medication) or HCV treatment-experienced (subject who has failed prior IFN or pegylated-interferon \[pegIFN\] with or without ribavirin \[RBV\], or sofosbuvir \[SOF\] plus RBV with or without pegIFN). GT3 subjects must be HCV treatment-naïve. Previous HCV treatment must have been completed greater than or equal to 2 months prior to Screening.~5. Subjects naïve to antiretroviral treatment (ART) must have CD4+ count greater than or equal to 500 cells/mm\^3 (or CD4+ % greater than or equal to 29%) at Screening; or Subjects on a stable ART regimen must have~   * CD4+ count greater than or equal to 200 cells/mm\^3 (or CD4+ % greater than or equal to 14%) at Screening; and~  * Plasma HIV-1 RNA below lower limit of quantification (LLOQ) at Screening and at least once during the 12 months prior to Screening.~Exclusion Criteria:~1. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.~2. Positive test result at Screening for hepatitis B surface antigen (HBsAg).~3. Positive Human Immunodeficiency virus, type 2 (HIV-2) Ab at Screening.~4. Receipt of any other investigational or commercially available direct acting anti-HCV agents other than sofosbuvir (e.g., telaprevir, boceprevir, simeprevir, paritaprevir, grazoprevir, daclatasvir, ledipasvir, ombitasvir, elbasvir or dasabuvir).~5. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT-493/ABT-530.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ABT-493/ABT-530 for 8 weeks (Type: EXPERIMENTAL): HCV Genotype (GT)1-6/HIV-1 co-infected non-cirrhotic subjects treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 8 weeks
- ABT-493/ABT-530 for 12 weeks (Type: EXPERIMENTAL): HCV GT1-6/HIV-1 co-infected subjects with compensated cirrhosis treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male, 18-65 years of age.~* Able and willing to take the active or placebo capsules over the whole study period.~* Health care professionals with essential patient contact (physicians, nurses, physiotherapists, etc) in Berlin, Germany.~* Written informed consent.~Exclusion Criteria:~* Known or suspected hypersensitivity or allergy to one of the ingredients of Juice Plus+®.~* Refusal to stop intake of additional vitamin supplements during study.~* Pregnancy or Lactation.~* Alcohol addiction, drug abuse or any other condition considered by the investigator to interfere with study procedures.~* Language limitations regarding interviews and questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Juice Plus (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Generalized Neonatal Screening of Severe Combined Immunodeficiencies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Screening Group: Newborn on day 3 of birth (premature and non premature)~* Control group: Patients diagnosed with SCID without screening at participating centers~Exclusion Criteria:~* Lack of parental consent~* Children whose parents are adults under guardianship,~* Children without health insurance, for the screening group:~* The early exit of the child from the maternity hospital

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Screened patients (Type: EXPERIMENTAL): SCID screening: more drops of blood are placed on a second Guthrie card when current screening (72 hours of life ) is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
- Control group (Type: NO_INTERVENTION): SCID children diagnosed without screening by pediatricians local referents DIP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, between the ages of 18 to 65 years~* Diagnosis of migraine, with or without aura~* Experiences between 1 and 8 migraine attacks per month for the past 12 months~Exclusion Criteria:~* Inability to distinguish other headaches from migraine~* Experiences headache of any kind at a frequency greater than or equal to 15 days per month~* History of resistance to sumatriptan, or non-response to 2 or more other triptans, defined as subjects who have not responded to an adequate dose and duration of treatment~* Current use of medication for migraine prophylaxis that has not been stable (no dose adjustment) for 30 days prior to screening~* Chronic opioid therapy (\>3 consecutive days in the 30 days prior to screening)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sumatriptan (Type: ACTIVE_COMPARATOR): None
- Matching placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Dental Caries Arrest Treatment in Primary Teeth Using AgNO3 Followed by NaF Varnish

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Kindergarteners who have joined our outreach dental service will be invited to join this study. Preschool children aged 3-4 years who have tooth decay and are attending the first year of kindergarten will be invited to join this study.~Exclusion Criteria:~* Children who are uncooperative and difficult to manage, have major systemic diseases, or are on long-term medication will be excluded.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Silver nitrate (Type: EXPERIMENTAL): Biannual application of 25% AgNO3 solution followed by 5% NaF varnish.
- Silver diamine fluoride (Type: ACTIVE_COMPARATOR): Biannual application of 38% SDF solution followed by placebo varnish.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged \>= 18 years.~* Patients with severe persistent allergic asthma with the following characteristics:~* FEV1 (Forced Expiratory Volume in One Second) \<80% of predicted.~* Frequent daily symptoms (\>=4 days/week on average) or nocturnal awakening (\>=1/week on average).~* Multiple severe asthma exacerbations: either \>=2 severe asthma exacerbations having required an unscheduled medical intervention with systemic corticosteroid in the past year, or hospitalization (including emergency room treatment) for an asthma exacerbation in the past year.~* Despite a high dose inhaled corticosteroid \>1000 mg beclomethasone dipropionate or equivalent and a inhaled long-acting B2-agonist.~* With an allergy to a perennial allergen demonstrated with convincing criteria, i.e. positive prick skin test or in vitro reactivity to a perennial aeroallergen (RAST).~* Total serum IgE level \>= 30 to \<=700 IU/ml and suitable serum total IgE level and weight according to Xolair dosing tablets.~Exclusion Criteria:~* Age \< 18 years.~* Smoking history \> 20 pack years.~* Patients who have had an asthma exacerbation during the 4 weeks prior to randomization~* History of food or drug related severe anaphylactoid or anaphylactic reaction~* Elevated serum IgE levels for reasons other than allergy (e.g. parasite infections, hyperimmunoglobulin E syndrome, Wiskott-Aldrich Syndrome or allergic bronchopulmonary aspergillosis).~* Patients with active cancer, suspicion of cancer or any history of cancer.~* Pregnant women.~* Known hypersensitivity to omalizumab or to one of its components.~* Patients already treated with omalizumab (indeed a previous treatment with omalizumab could have modified the FceRI expression).~* Patients who had participated in a clinical trial in the past 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: ACTIVE_COMPARATOR): Omalizumab was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. patients aged at least 18 years at the date of signing the consent form~2. diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the study~3. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy~4. able to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigator's decision)~5. willing and able to provide written informed consent (in accordance with Good Clinical Practice and local legislation).~Exclusion Criteria:~1. are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial. Acceptable methods of birth control include the transdermal patch, oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner.~2. known or suspected secondary hypertension~3. mean seated systolic blood pressure (SBP) over 200 mmHg and/or mean seated diastolic blood pressure (DBP) over 120 mmHg at Visit 1 or 2 or mean seated SBP over 180 mmHg and/or mean seated DBP over 120 mmHg at the end of the run-in period (Visit 3)~4. any clinically significant hepatic impairment (e.g. clinically significant cholestasis, biliary obstructive disorder or hepatic insufficiency)~5. severe renal impairment (e.g. serum creatinine \>3.0 mg/dL or \>265 mcmol/L, known creatinine clearance \<30mL/min or clinical markers of severe renal impairment)~6. bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant~7. clinically relevant hyperkalaemia~8. uncorrected volume or sodium depletion.~9. primary aldosteronism.~10. hereditary fructose or lactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
General Inclusion Criteria:~* Age ≥18 years and ≤85 years~* Patient or patient's legal representative is informed of the nature of the study, agrees to participate and has signed an EC approved consent form~Angiographic Inclusion Criteria:~- Target vessel is the superficial femoral artery and/or proximal popliteal artery (above the knee)~General Exclusion Criteria:~* Patient unwilling or unlikely to comply with follow-up schedule~* Stroke or STEMI within 3 months prior enrolment~Angiographic Exclusion Criteria:~- Acute or sub-acute thrombus in the target vessel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Drug-Coated Balloon (DCB) (Type: EXPERIMENTAL): IN.PACT Admiral: Balloon Angioplasty
- Standard PTA (Type: ACTIVE_COMPARATOR): Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who had failed H.pylori eradication therapies before.~2. Age between 18\~70, both gender.~3. Patients who had failed H.pylori eradication therapies during last 2 years and stop the eradication therapies for at least 3 months.~4. Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.~Exclusion Criteria:~1. Patients are excluded if they have previously used tetracycline and furazolidone antibiotics to eradicate infection with H. pylori.~2. Contraindications to study drugs.~3. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.~4. Constant use of anti-ulcer drugs ( including taking proton-pump. inhibitors(PPI) within 2 weeks before the \[13C\] urea breath test), antibiotics or bismuth complexes (more than 3 times /1 month before screening).~5. Pregnant or lactating women.~6. Underwent upper gastrointestinal Surgery.~7. Patients with moderate or severe atypical hyperplasia or high-grade intraepithelial neoplasia.~8. have symptom of dysphagia.~9. Evidence of bleeding or iron efficiency anemia.~10. A history of malignancy.~11. Drug or alcohol abuse history in the past 1 year.~12. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg/d).~13. a person with a mental disorder.~14. Enrolled in other clinical trials in the past 3 months.~15. Refuse to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- High-dose esomeprazole and amoxicillin dual therapy (Type: EXPERIMENTAL): Esomeprazole 40 mg and amoxicillin 1000 mg by mouth，three time daily for 14 days
- Bismuth-containing quadruple therapy (Type: ACTIVE_COMPARATOR): Tetracycline 500mg three time daily for 14 days，furazolidone 100 mg, esomeprazole 40 mg, and Bismuth 220mg by mouth, twice daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Male or female ≥40 years of age. BMI ≤ 40 kg/m2. Radiographically documented OA with Kellgren-Lawrence severity Grade 2 or 3 and associated symptoms Patient-reported pain with NRS score ≥4 (on a 0-10 scale) Able to read, understand, and sign the informed consent form, communicate with the investigator, complete study diaries, and understand and comply with protocol requirements.~Exclusion Criteria:~Recent use of IA or systemic corticosteroids Patient who is not ambulatory Any surgery or arthroscopy in the index knee within 12 months Any condition that could possibly confound the patient's assessment of index knee pain Substance abuse disorder, or positive urine drug test for illegal drug substances History of acquired or congenital immunodeficiency diseases History of treated malignancy which is disease free for ≤5 years Known allergy or hypersensitivity to the study drugs or their components

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TLC599 (Type: EXPERIMENTAL): TLC599 (1mL) IA injection
- Dexamethasone sodium phosphate (Type: ACTIVE_COMPARATOR): DSP 4mg (1mL) IA injection
- Normal Saline (Type: PLACEBO_COMPARATOR): Normal saline (1mL) IA injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete